Defunct Company
Total Trials
12
As Lead Sponsor
11
As Collaborator
1
Total Enrollment
306
NCT00235482
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 8, 2005
Completion: Apr 21, 2006
NCT00438009
A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)
Start: May 16, 2007
Completion: Aug 28, 2009
NCT00636558
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
Start: Feb 29, 2008
Completion: Jan 12, 2012
NCT00832559
A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)
Start: Jan 27, 2009
Completion: Jul 28, 2011
NCT01227551
A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )
Phase: Phase 2
Start: Dec 29, 2011
Completion: Apr 6, 2016
NCT01636882
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
Start: Jul 3, 2012
NCT02043665
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
Start: Dec 18, 2013
Completion: Jan 10, 2020
NCT02316171
CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)
Start: Jan 16, 2015
Completion: Mar 14, 2016
NCT02307149
Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)
Start: May 5, 2015
Completion: Nov 5, 2019
NCT02565992
Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
Start: Dec 17, 2015
Completion: Nov 4, 2019
NCT02824965
Pembrolizumab + CVA21 in Advanced NSCLC
Role: Collaborator
Start: Aug 9, 2017
Completion: Oct 31, 2021
NCT03408587
CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)
Start: Jan 29, 2018
Completion: May 22, 2019